It was huge. Its light brown shell stood taller than the tip of my shoe. Its yellowish-green body stretched about an inch ...

A House Republican has filed a bill that says health-care providers could not “discriminate” against patients based on ...

CX-5461 is the first G-quadruplex (G4) stabilizer in development. It has shown promising activity in early-phase trials for ...

Calling it the “Health Care Medical Freedom Act,” a House Republican on Monday filed a bill that says health-care providers ...

Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The new bill, called the "Health Care Medical Freedom Act," would, in part, prohibit Florida providers from refusing to see ...

Learn more about whether Twist Bioscience Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

The past year saw a number of significant actions at the state and federal levels that could transform how health care is ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Senhwa Biosciences aims at multi-billion dollar global market with CX-5461 combined with ADC “Blockbuster” therapy: Taipei, Taiwan Tuesday, December 30, 2025, 18:00 Hrs [IST] ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...